참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | Bromobenzene | HCID 7961 | — |
| 반응물 | Potassium Carbonate | HCID 11430 | — |
| 반응물 | Triphenylphosphine | HCID 11776 | — |
| 반응물 | 5,6,7,8-Tetrahydroimidazo(1,2-a)pyrazine | HCID 13247046 | — |
| 반응물 | 2-Chloro-6,7-dimethoxy-3H-quinazolin-4-one | HCID 135456664 | — |
| 반응물 | HCID 178419040 | HCID 178419040 | — |
| 촉매 | palladium(II) acetate | HCID 167845 | — |
| 용매 | Dimethylformamide | HCID 6228 | — |
| 생성물 | Ammonium Hydroxide | HCID 14923 | — |
| 생성물 | HCID 178418711 | HCID 178418711 | — |
반응 단계
5,6,7,8-Tetrahydro-imidazo[1,2-a]pyrazine, prepared as described in PCT Application WO 01/44250, was coupled with 2-chloro-6,7-dimethoxy-3H-quinazolin-4-one 1b, as described herein. 2-(5,6-dihydro-8H-imidazo[1,2-a]pyrazin-7-yl)-6,7-dimethoxy-1H-quinazolin-4-one (150 mg, 0.46 mmol) was combined with bromobezene (97 μL, 0.92 mmol), potassium carbonate (127 mg, 0.92 mmol), palladium acetate (5 mg, 5 mol %), and triphenylphosphine (13 mg, 10 mol %) in DMF (6 mL). The mixture was heated in a 140° C. bath for 2 d, then concentrated onto silica gel followed by eluting with 300:10:1 CH2Cl2:MeOH:NH4OH) to afford 50 mg of 6,7-dimethoxy-2-(3-phenyl-5,6-dihydro-8H-imidazo[1,2-α]pyrazin-7-yl)-1H-quinazolin-4-one, 904, mp: >300° C, M+=403.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| 특허 번호 | US07091200B2 |
|---|
| 출처 데이터셋 | uspto-grants-2006_08 |
|---|
| ORD ID | ord-6647c4f09b6c419a9d4dc6d55a619a4e |
|---|
| 출처 메모 | uspto-grants-2006_08 |
|---|